This study is for adults aged 18 and older who have been newly diagnosed with Acute Myeloid Leukemia (AML). It's looking at whether taking two common heart medications, metoprolol or carvedilol (beta blockers) and lisinopril (an ACE inhibitor), can prevent heart damage that can be caused by daunorubicin, a chemotherapy drug often used for AML. You would be randomly assigned to either receive these preventive heart medications or not. The main goal is to see how many people in each group develop heart damage, measured by how well your heart pumps blood (Left Ventricular Ejection Fraction or LVEF) up to about six months after your last anthracycline treatment. The study status is currently unclear.

Study design

This is an interventional study planning to enroll 70 participants. You will be randomly assigned to one of two groups, and you will know which group you are in.

What's involved

You will have ECGs (heart tracings) and echocardiograms (heart ultrasounds) before and during the study. You will also have blood tests and complete questionnaires at several times. If you are in the preventive medication group, you will take metoprolol or carvedilol and lisinopril and keep a diary.

Compensation

Not stated in the trial record.

Follow-up

Your heart function will be measured from the start of the study through 90 days after your last anthracycline treatment, which is usually up to 6 months later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.